
Corcept Therapeutics (CORT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $1.01 | $0.81 | 24.7 % |
| Q2 | Jul 29, 2026 | $0.36 | $0.02 | 1700.0 % |
| Q1 | Apr 30, 2026 | $-0.30 | $-0.17 | -76.5 % |
| Q4 | Feb 24, 2026 | $0.20 | $0.31 | -35.5 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $340.47M | $334.93M | 1.65 % |
| Q2 | Jul 29, 2026 | $256.15M | $219.32M | 16.8 % |
| Q1 | Apr 30, 2026 | $164.90M | $183.78M | -10.3 % |
| Q4 | Feb 24, 2026 | $202.13M | $254.72M | -20.6 % |
Corcept Therapeutics (CORT) last issued guidance on November 3, 2026 for fiscal year 2026. The company guided revenue in the range of $1.1B - $1.2B for the period.
Compared to prior guidance, Corcept Therapeutics maintained its revenue forecast from a prior range of $1.1B - $1.2B.
Corcept Therapeutics has issued 19 guidance updates between February 28, 2023 and November 3, 2026. During this period, the company raised its outlook 12 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.81 | $0.02 | $-0.17 | $0.31 |
| Actual | $1.01 | $0.36 | $-0.30 | $0.20 |
| Surprise | +24.7% | +1700.0% | -76.5% | -35.5% |
| Revenue | ||||
| Estimate | $334.9M | $219.3M | $183.8M | $254.7M |
| Actual | $340.5M | $256.1M | $164.9M | $202.1M |
| Surprise | +1.65% | +16.8% | -10.3% | -20.6% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.14 | $0.78 | $0.80 | $1.01 |
| Revenue | ||||
| Consensus | $394.9M | $367.3M | — | — |